TriSalus Life Sciences Names Chief Business Officer

TriSalus Life Sciences has announced the appointment of Daniel Estay as its chief business officer, reporting to company CEO Mary Szela. The appointment deepens the leadership capabilities of the company, supporting its strategic shift to become a leader in oncology drug delivery. Prior to joining TriSalus Life Sciences, Estay was consulting for medical technology companies and also served as co-founder and CEO of SonoVascular Inc., a pre-clinical stage company focused on advancing the treatment of blood clots using intrasvascular ultrasound technology.

“Dan brings insight and capabilities with a deep understanding around how to build value for clinicians and patients, all while delivering stellar business results. His knowledge of interventional medicine is extensive and his track record supports his ability to create market leadership for products and brands on a global scale,” said Szela. “I’m thrilled to have Dan join TriSalus as a member of my leadership team. I know he has the capability and shares our collective commitment to advance the strategic mission of the company as we build our capabilities in oncology drug delivery.”
 
Throughout his career, Estay has held a variety of executive operational and commercial roles in health care, with extensive experience in interventional medical technology. He has established a strong record of accomplishment, creating leadership positions for products under his management. In addition to operating and commercial responsibilities, Estay has held roles in business development, where he was responsible for creating and executing M&A and licensing strategies to build aligned product portfolios and secure capital for investment. In more than a decade with Abbott, he held leadership positions in general management and business development, including 6 years overseeing Abbott’s vascular device business in Asia Pacific & Japan. Estay received his bachelor of science degree in business administration from Syracuse University and an MBA from the University of Miami.
 
“The technology platform at TriSalus is compelling and has the potential to significantly change the way in which we intervene and treat cancer by combining immuno-oncology therapies with specialized drug delivery devices,” said Estay. ”I’m very pleased to be joining the organization at such an important time and look forward to building the necessary capabilities to enhance the way we provide care for patients.”

The high intratumoral pressure created by the tumor microenvironment limits the flow and accumulation of therapy in solid tumors. Interventional medical devices employing Pressure-enabled Drug Delivery (PEDD) can improve drug delivery to the tumor by creating a favorable pressure gradient that penetrates the hostile tumor microenvironment and increases drug concentration in the tumor without increasing systemic toxicity. Locoregional infusion with the Surefire-patented technology has been used in nearly 8,000 procedures worldwide for liver cancer and can be applied to a variety of other high-pressure solid tumors.
 
TriSalus Life Sciences, previously known as Surefire Medical, is a privately held medical device firm in Westminster, Colo., focused on making the administration of cancer therapies safer and more effective for patients. The company created the Pressure-enabled Drug Delivery (PEDD) technology and is committed to developing other applications of the technology for use in other solid tumors and for the administration of immuno-oncology (IO) therapies. TriSalus Life Sciences was founded in 2011.